Open AccessMeasurement of the kinase mTOR expression in blood cell of patients with atopic dermatitis
Author(s) -
И. В. Елистратова,
Андрей Вячеславович Гречко,
Е. А. Горелова,
S. V. Potapova,
Sergey G. Morozov
Publication year - 2018
Publication title -
patogenez
Language(s) - English
Resource type - Journals
ISSN - 2310-0435
DOI - 10.25557/2310-0435.2018.03.142-146
Subject(s) - mtorc2 , pi3k/akt/mtor pathway , mtorc1 , mechanistic target of rapamycin , cancer research , medicine , biology , signal transduction , microbiology and biotechnology
В клетках крови больных атопическим дерматитом (АД) исследовали экспрессию белка mTOR методом проточной цитометрии. Установлено, что общий пул белка mTOR в лимфоцитах повышен при АД по сравнению с донорами. Экспрессия белка mTOR в CD4+ и CD8+ Т-лимфоцитах крови в период обострения АД выше, чем у доноров и больных в периоде ремиссии. Оба комплекса киназы mTOR (mTORC1 и mTORC2) участвуют в изменениях субпопуляций лимфоцитов при АД. Активация белков Raptor и Rictor (mTORC1 vs mTORC2) достоверно выше в лимфоцитах больных АД легкой и средней степени тяжести (по индексу SCORAD), чем у доноров. The kinase mTOR expression was studied in blood cells of patients with atopic dermatitis (AD) using flow cytometry. The total level of lymphocyte mTOR protein was increased in AD patients compared with healthy donors. The mTOR protein expression in CD4+ and CD8+ T cells was higher in patients with AD in a relapse than in donors and patients in a remission. Both mTORC1 and mTORC2 complexes formed by mTOR kinase were found to participate in lymphocyte disruption during AD. Activation of Raptor and Rictor proteins (from mTORC1 and mTORC2, respectively) was significantly increased in lymphocytes of patients with mild and moderate AD (according to the SCORAD index).